CN1140801C - 检测血液中淋巴细胞对特定抗原反应性的方法 - Google Patents
检测血液中淋巴细胞对特定抗原反应性的方法 Download PDFInfo
- Publication number
- CN1140801C CN1140801C CNB001137476A CN00113747A CN1140801C CN 1140801 C CN1140801 C CN 1140801C CN B001137476 A CNB001137476 A CN B001137476A CN 00113747 A CN00113747 A CN 00113747A CN 1140801 C CN1140801 C CN 1140801C
- Authority
- CN
- China
- Prior art keywords
- hole
- cell
- wavelength
- supernatant
- mtt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 74
- 102000036639 antigens Human genes 0.000 title claims abstract description 74
- 108091007433 antigens Proteins 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 25
- 210000004369 blood Anatomy 0.000 title claims abstract description 6
- 239000008280 blood Substances 0.000 title claims abstract description 6
- 238000001514 detection method Methods 0.000 title claims description 52
- 210000004698 lymphocyte Anatomy 0.000 title claims description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 181
- 230000009257 reactivity Effects 0.000 claims abstract description 6
- 238000002835 absorbance Methods 0.000 claims description 38
- 239000006228 supernatant Substances 0.000 claims description 37
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 22
- 238000011534 incubation Methods 0.000 claims description 19
- 230000001413 cellular effect Effects 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 16
- 238000010521 absorption reaction Methods 0.000 claims description 15
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 13
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 238000007789 sealing Methods 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 239000006285 cell suspension Substances 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 230000000527 lymphocytic effect Effects 0.000 claims description 6
- 229940113082 thymine Drugs 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- 238000006911 enzymatic reaction Methods 0.000 claims description 4
- 239000012930 cell culture fluid Substances 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 claims description 2
- 230000000994 depressogenic effect Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- -1 phenmethylol Chemical compound 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 abstract description 27
- 238000012544 monitoring process Methods 0.000 abstract description 8
- 239000003018 immunosuppressive agent Substances 0.000 abstract description 5
- 238000002054 transplantation Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 210000002751 lymph Anatomy 0.000 abstract 3
- 238000004113 cell culture Methods 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 206010070834 Sensitisation Diseases 0.000 description 13
- 230000008313 sensitization Effects 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 230000000877 morphologic effect Effects 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 5
- 238000006062 fragmentation reaction Methods 0.000 description 5
- 230000031700 light absorption Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 231100000933 sensitization response Toxicity 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000012364 Peperomia pellucida Nutrition 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims (12)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001137476A CN1140801C (zh) | 2000-03-01 | 2000-03-01 | 检测血液中淋巴细胞对特定抗原反应性的方法 |
GB0220171A GB2375395A (en) | 2000-03-01 | 2001-01-18 | A method for detecting the reactivity of lymphocyte in blood to a specific antgen |
DE10195824T DE10195824T5 (de) | 2000-03-01 | 2001-01-18 | Verfahren zur Bestimmung der Fähigkeit der Reaktion der Reaktion der Lymphozyten im Blut auf spezifisches Antigen |
US10/220,798 US20030108968A1 (en) | 2000-03-01 | 2001-01-18 | Method for detecting the reactivity of lymphocyte in blood to specific antigen |
JP2001563900A JP2003525452A (ja) | 2000-03-01 | 2001-01-18 | 血中リンパ球の特異抗原に対する反応性を決定するための方法 |
AU29998/01A AU2999801A (en) | 2000-03-01 | 2001-01-18 | A method for detecting the reactivity of lymphocyte in blood to a specific antigen |
PCT/CN2001/000064 WO2001065256A1 (fr) | 2000-03-01 | 2001-01-18 | Procede de detection de la reactivite des lymphocytes presents dans un echantillon de sang face aux antigenes specifiques |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001137476A CN1140801C (zh) | 2000-03-01 | 2000-03-01 | 检测血液中淋巴细胞对特定抗原反应性的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1311437A CN1311437A (zh) | 2001-09-05 |
CN1140801C true CN1140801C (zh) | 2004-03-03 |
Family
ID=4583504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB001137476A Expired - Fee Related CN1140801C (zh) | 2000-03-01 | 2000-03-01 | 检测血液中淋巴细胞对特定抗原反应性的方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20030108968A1 (zh) |
JP (1) | JP2003525452A (zh) |
CN (1) | CN1140801C (zh) |
AU (1) | AU2999801A (zh) |
DE (1) | DE10195824T5 (zh) |
GB (1) | GB2375395A (zh) |
WO (1) | WO2001065256A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1444043A (zh) * | 2002-12-25 | 2003-09-24 | 帕弗瑞生物技术(北京)有限公司 | 一种个体化特异性免疫细胞功能测定方法 |
ATE482394T1 (de) * | 2006-06-15 | 2010-10-15 | Nat Univ Corp Tokyo Med & Dent | Verfahren, vorrichtung und programm zur bewertung der immunität sowie datenaufzeichnungsmedium mit darin gespeichertem immunitätsbewertungsprogramm |
JP5030109B2 (ja) * | 2008-12-18 | 2012-09-19 | 国立大学法人 東京医科歯科大学 | 免疫力評価方法、装置、及びプログラム |
CN101782576A (zh) * | 2010-03-12 | 2010-07-21 | 北京工业大学 | 电磁辐射诱发Raji细胞癌变的检测方法 |
CN117741162A (zh) * | 2024-02-20 | 2024-03-22 | 苏州才博医学科技有限公司 | 一种检测供者特异性抗体的细胞学方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1086646A (en) * | 1976-06-17 | 1980-09-30 | Marilyn L. Bach | Primed leukocyte typing |
CA1296622C (en) * | 1986-08-12 | 1992-03-03 | Jeffrey E. Anderson | Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system |
JPH05244993A (ja) * | 1992-03-06 | 1993-09-24 | Fuji Photo Film Co Ltd | 改良されたmtt比色定量方法 |
US5482841A (en) * | 1994-05-24 | 1996-01-09 | Sangstat Medical Corporation | Evaluation of transplant acceptance |
US5594116A (en) * | 1995-11-08 | 1997-01-14 | Promega Corporation | Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay |
EP0955366B1 (en) * | 1995-12-12 | 2006-09-06 | Takara Bio Inc. | Antigenic protein originating in malassezia |
US20020155117A1 (en) * | 1996-04-04 | 2002-10-24 | Nicole Suciu-Foca | Method for detecting organ allograft rejection and uses thereof |
-
2000
- 2000-03-01 CN CNB001137476A patent/CN1140801C/zh not_active Expired - Fee Related
-
2001
- 2001-01-18 JP JP2001563900A patent/JP2003525452A/ja active Pending
- 2001-01-18 WO PCT/CN2001/000064 patent/WO2001065256A1/zh active Application Filing
- 2001-01-18 DE DE10195824T patent/DE10195824T5/de not_active Ceased
- 2001-01-18 AU AU29998/01A patent/AU2999801A/en not_active Abandoned
- 2001-01-18 GB GB0220171A patent/GB2375395A/en not_active Withdrawn
- 2001-01-18 US US10/220,798 patent/US20030108968A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GB2375395A (en) | 2002-11-13 |
CN1311437A (zh) | 2001-09-05 |
DE10195824T5 (de) | 2004-07-08 |
GB0220171D0 (en) | 2002-10-09 |
JP2003525452A (ja) | 2003-08-26 |
US20030108968A1 (en) | 2003-06-12 |
AU2999801A (en) | 2001-09-12 |
WO2001065256A1 (fr) | 2001-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103422176B (zh) | 人羊膜间充质干细胞库的构建方法 | |
CN105008900A (zh) | 用于评价***和胚胎的代谢成像方法 | |
CN1140801C (zh) | 检测血液中淋巴细胞对特定抗原反应性的方法 | |
Danes et al. | Hurler's syndrome: Effect of retinol (vitamin A alcohol) on cellular mucopolysaccharides in cultured human skin fibroblasts | |
Evans et al. | Criteria for the diagnosis of vaginal candidosis: evaluation of a new latex agglutination test | |
CN104278077A (zh) | 一种高通量快速筛选罗氏沼虾免疫增强剂的方法 | |
CN101382549A (zh) | 一种结核分枝杆菌快速检测***及方法 | |
CN104122355A (zh) | 一种通过检测斑马鱼组织肌酐含量评价化合物肾脏毒性的方法 | |
CN203535053U (zh) | 用于检测nk细胞活性的试剂盒 | |
CN101250500A (zh) | 一种成人远端肺动脉平滑肌细胞的培养方法 | |
CN103269705A (zh) | 红色诺卡氏菌细胞壁骨架增强树突状细胞功能的方法 | |
CN101570739B (zh) | 银屑病基础研究模型的建立方法及气液平面跨膜装置 | |
CN1176377C (zh) | 糖尿病自身免疫抗体检测复合芯片及其制备、检测方法 | |
CN101993911B (zh) | 一种活性小分子核素探针平台及其在生物医学中的应用 | |
CN101858866A (zh) | 一种在活细胞内精确定量检测抗朊病毒药物作用效果的方法 | |
CN104142384A (zh) | 一种筛选具有保护或改善肾功能活性化合物的方法 | |
CN114414541A (zh) | 一种应用3d细胞成像分析***检测t细胞杀伤效力的方法 | |
CN208443738U (zh) | 一种新型结构的sers基底 | |
CN200996937Y (zh) | ***浓度快速诊断试剂盒 | |
CN212228958U (zh) | 痰液结核杆菌检测试剂套装 | |
Samaranayake et al. | Studying Candida albicans adhesion | |
CN103961339B (zh) | 新女贞子苷在抗阿霉素心肌毒性中的应用及以新女贞子苷为主要活性成分的药物组合物 | |
CN104293734A (zh) | 一种人γδT细胞的制备方法 | |
Kusel | The penetration of human epidermal sheets by the cercariae of Schistosoma mansoni and the collection of schistosomula | |
JP2681356B2 (ja) | チザー病菌の培養集菌方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHAANXI JIADI BIOLOGY TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: HU JUN Effective date: 20070216 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070216 Address after: 710054, Xi'an, Shaanxi province Xi'an science and Technology Park, four race building Patentee after: Shaanxi excinn Biotechnology Co., Ltd. Address before: Cardiac surgery in the Xijing Hospital Changle four West Road 710032 Shaanxi city of Xi'an Province Patentee before: Hu Jun |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Yanyi Document name: Notification to Pay the Fees |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |